Transgenic Flies Screen Mutant kRAS Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively target mutant kRAS proteins, which are frequently involved in cancer development and progression, due to the difficulty in inhibiting their constitutive activity and the complexity of their signaling pathways.
Innovation Solution
Transgenic flies harboring a RAS transgene are used to identify compounds that modulate kRAS activity, allowing for the screening of potential therapeutic agents that can inhibit neoplastic diseases by mimicking human kRAS mutations and observing phenotypic changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to target mutant kRAS, then therapeutic effectiveness against cancer should improve, but the patent notes that 25 years of work has not yielded a successful molecule due to the difficulty of inhibiting constitutive activity and protein-protein interaction complexity
Solution Approach 1:
The patent uses transgenic flies as an intermediary model system to screen for compounds that can inhibit mutant kRAS activity. The fly model serves as a simplified mediator between the complex human cancer system and drug testing, allowing identification of effective inhibitors without directly confronting the full complexity of human RAS signaling pathways initially.
Solution Approach 2:
The patent creates a simplified copy of the human kRAS mutation system in Drosophila melanogaster. By introducing human kRAS transgenes into flies and observing phenotypic effects, the invention replicates the essential features of mutant kRAS activity in a more tractable model organism, enabling drug screening without the full complexity of human cellular systems.
2Ease of operation
If direct targeting of kRAS protein-protein interactions is attempted, then specific inhibition of mutant kRAS should be achieved, but the patent states that PPIs are challenging to target because of the featureless topologies of the surfaces involved
Solution Approach 1:
The patent copies the essential protein-protein interaction features of mutant kRAS into a simplified fly model system. By reproducing the key interaction phenotypes in Drosophila, the invention makes the otherwise intractable PPI targeting problem measurable and screenable in a more accessible biological system.
Solution Approach 2:
The patent replaces the difficult-to-target physical protein-protein interaction interface with a genetic model system where the effects of inhibition can be observed through phenotypic changes in flies. This substitutes direct mechanical PPI measurement with genetic/phenotypic readouts that are easier to detect and measure.
3Productivity
If transgenic fly models are used to screen for kRAS inhibitors, then compound identification efficiency should improve, but the patent requires stable integration of transgenes and controlled expression to achieve reliable phenotypic observation
Solution Approach 1:
The patent performs preliminary actions by first establishing stable transgenic fly lines with integrated kRAS transgenes before conducting compound screens. The transgenes are pre-integrated into the fly genome and pre-expressed under controlled promoters, creating a ready-to-screen model system that eliminates the need for repeated transgene integration during each screening experiment.
Solution Approach 2:
The transgenic fly model serves itself by maintaining stable transgene integration and controlled expression across generations. Once the transgenic line is established, it automatically provides the necessary phenotypic readouts for compound screening without requiring repeated manual intervention for transgene integration or expression control.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Non-mammalian, transgenic animals, e.g., flies, that include a RAS transgene, are provided. Also provided are methods of using the subject transgenic non-mammalian animals to identify compounds having activity with respect to cellular proliferative, such as neoplastic, diseases.